Summary by Moomoo AI
On March 27, 2024, Avalo Therapeutics, Inc. announced the completion of a strategic acquisition and a significant private placement financing. The company acquired AlmataBio, Inc., a biotechnology firm with a Phase 2-ready anti-IL-1β monoclonal antibody, AVTX-009, aimed at treating inflammatory diseases. The acquisition was a stock-for-stock transaction valued at approximately $15 million. Concurrently, Avalo entered into a securities purchase agreement with institutional investors for a private placement financing of up to $185 million, with an initial investment of $115.6 million. The proceeds are expected to extend Avalo's cash runway into 2027 and will be used for milestone payments to Almata stockholders and general corporate purposes. The private placement is expected to close on March 28, 2024. As part of the agreement, Avalo issued 171,605 shares...Show More